Virtual Library

Start Your Search

L. Li

Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P013 - Anti-PD-1 Combination (ID 85)

      00:00 - 00:00  |  Author(s): L. Li

      • Abstract

      Effective treatment options are limited for advanced non-small cell lung cancer (NSCLC) patients who progressed after first-line therapy. Pronounced efficacy of anti-programmed cell death protein 1 (anti-PD-1) combination strategy was observed in first-line setting, therefore we assessed whether the addition of chemotherapy and/or bevacizumab to anti-PD-1 could improve clinical outcomes in second-line or later advanced NSCLC.

      Advanced NSCLC patients treated with anti-PD-1 therapy from March 2015 to July 2017 were retrospectively screened for eligibility. First-line treatment or combined drugs beyond chemotherapy or bevacizumab were excluded. The primary objective was progression-free survival (PFS). Secondary objectives were overall response rate (ORR), disease control rate (DCR) and safety.

      55 patients were included in the analysis (monotherapy, n=33; combination therapy, n=22). 90.0% of the patients have progressed after standard platinum-based chemotherapy in previous line therapies. Combination group exhibited longer PFS than monotherapy group (median, 7.5 vs 3.3 months, adjusted HR 0.32[0.16-0.65], P =0.001). 31.8% (7/22) patients in combination group achieved an objective response compared with 10.0% (3/30) in monotherapy group (P = 0.075). The DCR was 95.5% (21/22) in combination group compared with 46.7% (14/30) in monotherapy group (P<0.001). Adverse events of grade 3 or worse were occurred in 22.7% of the patients in the combination group and in 6.1% of those in monotherapy group. Most of the adverse events were manageable.

      Combination of anti-PD-1 plus chemotherapy and/or bevacizumab could be an effective and tolerable therapy as second-line or later treatment option for advanced NSCLC patients.